Rayence Co

Rayence Co Financing Cash Flow

The Net Financing Cash Flow of Rayence Co (228850.KQ) as of Nov 7, 2026 is -17.26 B KRW. In the previous year, Net Financing Cash Flow was -3.69 B KRW — a change of 367.62% (lower).

Financing Cash Flow

-17.26 BKRW

YoY

367.62%

Last updated:

Net Financing Cash Flow of Rayence Co is 2024 -17.26 B KRW. Net Financing Cash Flow of Rayence Co was 2023 -3.69 B KRW. It decreases by 367.62% lower compared to the previous year.

The Rayence Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
-5.74 B KRW
Jan 1, 2018
-14.32 B KRW
Jan 1, 2019
10.69 B KRW
Jan 1, 2020
-3.88 B KRW
Jan 1, 2021
-2.39 B KRW
Jan 1, 2022
-3.62 B KRW
Jan 1, 2023
-3.69 B KRW
Jan 1, 2024
-17.26 B KRW
The Rayence Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
-17.26 BKRW+367.62%
-3.69 BKRW+1.85%
-3.62 BKRW+51.73%
-2.39 BKRW-38.42%
-3.88 BKRW-136.28%
10.69 BKRW-174.64%
-14.32 BKRW+149.63%
-5.74 BKRW-107.18%
79.95 BKRW+3,914.63%
1.99 BKRW-373.93%
-727.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Net Financing Cash Flow of Rayence Co is -17.26 B KRW in 2024.

Net Financing Cash Flow of Rayence Co changed from -3.69 B KRW to -17.26 B KRW, representing a 367.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Rayence Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rayence Co

All Key Metrics — Rayence Co